The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease

Crizanlizumab is a monoclonal antibody that binds to P-selectin. On October 28, 2020, a conditional marketing authorization valid through the European Union (EU) was issued for crizanlizumab for the prevention of recurrent vaso-occlusive crises (VOCs) in patients with sickle cell disease aged 16 yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado, Julio, Voltz, Caroline, Stain, Milena, Lapveteläinen, Tuomo, Urach, Susanne, Lähteenvuo, Johanna, Penttilä, Karri, Gisselbrecht, Christian, Enzmann, Harald, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240778/
https://www.ncbi.nlm.nih.gov/pubmed/34235401
http://dx.doi.org/10.1097/HS9.0000000000000604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240778/
https://www.ncbi.nlm.nih.gov/pubmed/34235401
http://dx.doi.org/10.1097/HS9.0000000000000604

Ejemplares similares